Dublin, Feb. 09, 2017 -- Research and Markets has announced the addition of the "Norovirus Forecast for selected Asian Markets 2017-2027" report to their offering.
Currently, there are six recognized norovirus genogroups, three of which (GI, GII, and GIV) affect humans. More than 25 different genotypes have been identified within these three genogroups. Variants of the GII.4 genotype are the most common cause of norovirus outbreaks.
This report provides the current incident population for Norovirus across Selected Asian Markets (Cambodia, Indonesia, Lao PDR and Vietnam) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms of Norovirus have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Signs and symptoms of norovirus infection include:
- Nausea
- Vomiting
- Abdominal pain or cramps
- Watery or loose diarrhoea
- Malaise
- Low-grade fever
- Muscle pain
Reasons to Buy:
- Able to quantify patient populations in global Norovirus's market to target the development of future products, pricing strategies and launch plans.
- Gain further insight into the incidence of the subdivided types of Norovirus and identify patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Identify sub-populations within Norovirus which require treatment.
- Gain an understanding of the specific markets that have the largest number of Norovirus patients.
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Methodology for quantification of patient numbers
8. Top-line Estimated Incidence for Norovirus
9. Norovirus in Vietnam
10. Abbreviations used in the report
11. Patient-Based Offering
12. Online Pricing Data and Platforms
13. References
14. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/q7lfn6/norovirus
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infectious Diseases Drugs, Gastrointestinal Drugs


OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Washington Post Publisher Will Lewis Steps Down After Layoffs 



